Actively Recruiting
Real World Evidence Clinical Utility Study of KidneyIntelX
Led by Renalytix AI, Inc. · Updated on 2024-04-12
10000
Participants Needed
1
Research Sites
300 weeks
Total Duration
On this page
Sponsors
R
Renalytix AI, Inc.
Lead Sponsor
M
Mount Sinai Hospital, New York
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to assess the impact of the KidneyIntelX assay utilized as part of the current standard of care on the management of patients seen in the primary care physician's office at Mount Sinai.
CONDITIONS
Official Title
Real World Evidence Clinical Utility Study of KidneyIntelX
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Individuals with Type 2 diabetes and concurrent chronic (diabetic) kidney disease (G3a-G3b or G1-G2, A2-A3) per KDIGO CKD staging.
You will not qualify if you...
- Patients without the appropriate characteristics as identified in the KidneyIntelX intended use population.
- Patients with eGFR <30 or 260 ml/min/1.73m2 without albuminuria.
- Patients with ESRD or on renal recovery treatments at time of enrollment.
- Patients who are pregnant at the time of enrollment.
- Patients who are currently hospitalized.
- Patients without minimum 6 month pre-baseline KidneyIntelX medical history.
- Patients who are currently on Enbrel.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mount Sinai Health System
New York, New York, United States, 10029
Actively Recruiting
Research Team
R
Roger Tun
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here